You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.
The mutations in these underappreciated noncanonical genes were overrepresented in the E. coli genomes, indicating they were clinically relevant.
Using whole-genome sequence data for thousands of African American individuals, researchers teased out ancestry effects on polygenic risk of the conditions.
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.
Andrew Brooks, a Rutgers University professor involved in the development of saliva-based tests for SARS-CoV-2, has died at 51, People reports.
In PNAS this week: study of gene mutation implicated in deafness, examination of codon origins, and more.
Five tenured Rutgers University professors are suing the school over pay disparities, according to the New York Times.
The new company, called Infinity Biologix, will continue to operate out of Rutgers' New Brunswick campus with over 400 technicians and scientists.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.